socalTECH

SEPTEMBER 20, 2010

Los Angeles-based Internet Brands , which operates a suite of online, advertising driven websites across a wide range of verticals, said Monday that it would go private in a $640M, private equity deal, bucking the trend of Southern California companies filing to get to the public markets. Internet Brands had gone public just three years ago.

Internet Brands 190

Internet Brands Westlake Village Woodland Hills Beverly Hills 190

Xconomy

SEPTEMBER 30, 2016

Who will be first to market with a new type of cancer treatment known as CAR-T? TOP STORIES : —Kite Pharma (NASDAQ: KITE ) released data from an ongoing non-hodgkin lymphoma trial that, while early, bolster the view that the Santa Monica, CA, company could be the first to market with a cell-based immunotherapy product known as CAR-T.

Avalon 40

Avalon Thousand Oaks Study Startup 40

Xconomy

AUGUST 26, 2016

Two days later, it paid AstraZeneca $550 million upfront for the rights to a group of antibiotics either already on the market or in late-stage testing. It will retain the PixarBio name and aims to start trading on the over-the-counter market during the second week of September.

Pricing 40

Pricing Thousand Oaks Startup Research 40

Xconomy

JULY 22, 2016

Xconomy spoke with CEO Tom Hughes about the decision, which is terrible news for patients with the rare disease Prader-Willi Syndrome; Zafgen had hoped to win FDA approval of beloranib in Prader-Willi, which would have made it the first marketed drug for the disease since human growth hormone over a decade ago.

Startup 40

Startup San Diego News Thousand Oaks 40

Xconomy

AUGUST 5, 2016

As a result, Biogen will buy the rights to nusinersen and prepare to ask regulators for marketing approval. Adicet raised $51 million earlier this year… Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, is paying $40 million immediately for rights to ADXS-NEO , a preclinical cancer treatment from Princeton, NJ-based Advaxis (NASDAQ: ADXS ).

News 40

News Thousand Oaks Pricing Report 40

Xconomy

JUNE 10, 2016

—On the positive side, Thousand Oaks, CA-based Amgen (NASDAQ: AMGN ) released an overview of Phase 2 data that showed its migraine prevention drug, erenumab, is keeping pace with rival drugs in a heated race to market. The full data set has yet to be released.

Incubator 67

Incubator Thousand Oaks Screening Pricing 67